BCM
PDSB icon

BlueCrest Capital Management’s PDS Biotechnology PDSB Stock Holding History

BlueCrest Capital Management’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-655
Closed -$11K – 1286
2018
Q3 		$11K Buy
+655
New +$11.8K ﹤0.01% 1465

Other funds holding PDSB

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

BlueCrest Capital Management's PDSB Position: Q4 2018 in Review

BlueCrest Capital Management sold out of PDS Biotechnology (PDSB) in Q4 2018, closing a stake of 655 shares — an estimated $11K sold.

BlueCrest Capital Management first reported a position in PDSB in Q3 2018 and held it in 1 quarter. The position peaked at $11K in Q3 2018. 31 funds tracked by Wall St. Rank hold PDSB as of Q4 2018.

  • BlueCrest Capital Management reported no remaining PDS Biotechnology position as of Q4 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 655 PDS Biotechnology shares in Q4 2018, an estimated $11K.
  • BlueCrest Capital Management first reported a position in PDS Biotechnology in Q3 2018 and held it in 1 quarter.
  • BlueCrest Capital Management's PDS Biotechnology position peaked at $11K in Q3 2018.
  • 31 funds tracked by Wall St. Rank held PDS Biotechnology as of Q4 2018.

Based on BlueCrest Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.